Senseonics Unveils Eversense Bridge Program In The U.S.
Zacks Investment Research | Mar 24, 2019 10:42PM ET
Senseonics Holdings, Inc. (NYSE:SENS) recently announced the commercial launch of the Eversense Bridge Patient Access Program in the United States. This program will enable diabetic patients access the company’s newly-approved Eversense continuous glucose monitoring (CGM) system, for $99, in addition to the cost of sensor placement.
The program is in sync with Senseonics’ strategy to offer advanced and affordable medical care to diabetic patients.
Senseonics is a global medical technology company specializing in the innovation and commercialization of implantable CGM systems for people living with diabetes.
More on the Eversense CGM System
The Eversense CGM system is an upgraded version of traditional CGM model in the market as it is the first and only implantable CGM sensor that is designed to last up to 90 days. It is equipped with a smart transmitter and a mobile app that facilitate discreet vibratory data alerts for high and low levels of blood glucose.
About the Eversense Bridge Program
The primary goal of the Eversense Bridge program is to enable easy access to this advanced diabetes management technology by confirming patients’ insurance coverage benefits, acquiring their authorization prior to sensor placement and helping them with appeals of denied claims.
Market Prospects
The global market of continuous glucose monitoring system is projected to reach a worth of $4.9 billion at a CAGR of 22.9% during the forecasted period of 2018-2024.
Recent Developments
Since Senseonics’ receipt of FDA approval for Eversense CGM system last July, the company is constantly expanding it commercially. In November, the company received FDA approval to expand Eversense CGM certification to nurse practitioners and physician assistants.
More recently, Senseonics integrated Eversense CGM data into the diabetes data management platform of Glooko. The company also announced a partnership with Geo-Med, LLC,a verified Service-Disabled Veteran-Owned Small Business, to extend coverage of its Eversense CGM to more than 9 million insured U.S. veterans and government staff. Last October, Aetna (NYSE:AET), the third-largest health insurance provider in the United States, agreed to provide coverage for the Eversense CGM system.
Price Performance
Over the past year, Sensonic has underperformed the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.